Roy Xiao1, Matthew C Ward2, Kailin Yang1,3, David J Adelstein4, Shlomo A Koyfman3, Brandon L Prendes5, Brian B Burkey5. 1. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, Ohio. 2. Southeast Radiation Oncology Group, Charlotte, North Carolina. 3. Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. 4. Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. 5. Section of Head and Neck Surgery and Oncology, Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio.
Abstract
BACKGROUND: Time to treatment initiation (TTI) is increasing and is associated with worsening survival. In the current study, the authors sought to identify a mechanism for this relationship by assessing the effect of TTI on clinical-to-pathologic upstaging in patients with head and neck squamous cell carcinoma (HNSCC). METHODS: Using the National Cancer Data Base, the authors analyzed patients receiving definitive surgery for SCC of the oral cavity, oropharynx, larynx, and hypopharynx from 2005 through 2014. The primary outcome was T, N, or stage group upstaging, defined as higher pathologic stage than clinical stage. TTI was defined as the time between diagnosis and surgery. Multivariable logistic and Cox proportional hazards regression modeled upstaging and survival, respectively. RESULTS: Cohorts of 60,194 patients, 51,380 patients, and 52,980 patients, respectively, with complete T, N, and stage group data were included. N upstaging was most common (18.6%), followed by stage group (17.4%) and T (12.1%) upstaging; all types were predicted by TTI. Compared with a TTI of 1 to 6 days, TTIs as short as 7 to 13 days (odds ratio, 1.20; P = .038) or ≥ 70 days (odds ratio, 2.04; P < .001) were found to predict T upstaging, a finding that is consistent for N and stage group upstaging. Using restricted cubic splines, relative odds of T and stage group upstaging escalated to 2.25 and 1.93, respectively, at a TTI of 365 days. In survival analyses, T (hazard ratio [HR], 1.53), N (HR, 1.88), and stage group (HR, 1.69) upstaging all predicted mortality (P < .001), whereas TTI only predicted mortality after 70 days (HR, 1.11; P = .023). CONCLUSIONS: Tumor progression, measured by clinical-to-pathologic upstaging, increases mortality for patients with HNSCC experiencing treatment delays. Cancer 2018;124:1400-14.
BACKGROUND: Time to treatment initiation (TTI) is increasing and is associated with worsening survival. In the current study, the authors sought to identify a mechanism for this relationship by assessing the effect of TTI on clinical-to-pathologic upstaging in patients with head and neck squamous cell carcinoma (HNSCC). METHODS: Using the National Cancer Data Base, the authors analyzed patients receiving definitive surgery for SCC of the oral cavity, oropharynx, larynx, and hypopharynx from 2005 through 2014. The primary outcome was T, N, or stage group upstaging, defined as higher pathologic stage than clinical stage. TTI was defined as the time between diagnosis and surgery. Multivariable logistic and Cox proportional hazards regression modeled upstaging and survival, respectively. RESULTS: Cohorts of 60,194 patients, 51,380 patients, and 52,980 patients, respectively, with complete T, N, and stage group data were included. N upstaging was most common (18.6%), followed by stage group (17.4%) and T (12.1%) upstaging; all types were predicted by TTI. Compared with a TTI of 1 to 6 days, TTIs as short as 7 to 13 days (odds ratio, 1.20; P = .038) or ≥ 70 days (odds ratio, 2.04; P < .001) were found to predict T upstaging, a finding that is consistent for N and stage group upstaging. Using restricted cubic splines, relative odds of T and stage group upstaging escalated to 2.25 and 1.93, respectively, at a TTI of 365 days. In survival analyses, T (hazard ratio [HR], 1.53), N (HR, 1.88), and stage group (HR, 1.69) upstaging all predicted mortality (P < .001), whereas TTI only predicted mortality after 70 days (HR, 1.11; P = .023). CONCLUSIONS: Tumor progression, measured by clinical-to-pathologic upstaging, increases mortality for patients with HNSCC experiencing treatment delays. Cancer 2018;124:1400-14.
Authors: Roy Xiao; Rohan R Joshi; Qasim Husain; Jennifer R Cracchiolo; Nancy Lee; Jillian Tsai; Yao Yu; Linda Chen; Jung J Kang; Sean McBride; Nadeem Riaz; Benjamin R Roman; Ian Ganly; Viviane Tabar; Stacey T Gray; Marc A Cohen Journal: Head Neck Date: 2019-07-11 Impact factor: 3.147
Authors: Helmneh M Sineshaw; Mark A Ellis; K Robin Yabroff; Xuesong Han; Ahmedin Jemal; Terry A Day; Evan M Graboyes Journal: JAMA Otolaryngol Head Neck Surg Date: 2020-03-01 Impact factor: 6.223
Authors: Gregory S Weinstein; Roger Cohen; Alexander Lin; Bert W O'Malley; John Lukens; Samuel Swisher-McClure; Rabie M Shanti; Jason G Newman; Harman S Parhar; Kendall Tasche; Robert M Brody; Ara Chalian; Steven Cannady; James N Palmer; Nithin D Adappa; Michael A Kohanski; Joshua Bauml; Charu Aggarwal; Kathleen Montone; Virginia Livolsi; Zubair W Baloch; Jalal B Jalaly; Kumarasen Cooper; Karthik Rajasekaran; Laurie Loevner; Christopher Rassekh Journal: Head Neck Date: 2020-06-25 Impact factor: 3.147
Authors: Chandler J Rygalski; Songzhu Zhao; Antoine Eskander; Kevin Y Zhan; Edmund A Mroz; Guy Brock; Dustin A Silverman; Dukagjin Blakaj; Marcelo R Bonomi; Ricardo L Carrau; Matthew O Old; James W Rocco; Nolan B Seim; Sidharth V Puram; Stephen Y Kang Journal: Ann Surg Oncol Date: 2020-11-13 Impact factor: 5.344
Authors: Michael M Li; Songzhu Zhao; Antoine Eskander; Chandler Rygalski; Guy Brock; Anuraag S Parikh; Catherine T Haring; Brian Swendseid; Kevin Y Zhan; Carol R Bradford; Theodoros N Teknos; Ricardo L Carrau; Kyle K VanKoevering; Nolan B Seim; Matthew O Old; James W Rocco; Sidharth V Puram; Stephen Y Kang Journal: Ann Surg Oncol Date: 2021-07-15 Impact factor: 4.339
Authors: Michael C Topf; Jared A Shenson; F Christopher Holsinger; Samuel H Wald; Lisa J Cianfichi; Eben L Rosenthal; John B Sunwoo Journal: Head Neck Date: 2020-05-06 Impact factor: 3.147
Authors: John R de Almeida; Christopher W Noel; David Forner; Han Zhang; Anthony C Nichols; Marc A Cohen; Richard J Wong; Caitlin McMullen; Evan M Graboyes; Vasu Divi; Andrew G Shuman; Andrew J Rosko; Carol M Lewis; Ehab Y Hanna; Jeffrey Myers; Vinidh Paleri; Brett Miles; Eric Genden; Antoine Eskander; Danny J Enepekides; Kevin M Higgins; Dale Brown; Douglas B Chepeha; Ian J Witterick; Patrick J Gullane; Jonathan C Irish; Eric Monteiro; David P Goldstein; Ralph Gilbert Journal: Cancer Date: 2020-08-11 Impact factor: 6.860
Authors: Aline Lauda Freitas Chaves; Ana Ferreira Castro; Gustavo Nader Marta; Gilberto Castro Junior; Robert L Ferris; Raúl Eduardo Giglio; Wojciech Golusinski; Philippe Gorphe; Sefik Hosal; C René Leemans; Nicolas Magné; Hisham Mehanna; Ricard Mesía; Eduardo Netto; Amanda Psyrri; Assuntina G Sacco; Jatin Shah; Christian Simon; Jan B Vermorken; Luiz Paulo Kowalski Journal: Oral Oncol Date: 2020-04-24 Impact factor: 5.337